Letolizuman/BMS-986004, a novel anti-human CD154 domain antibody that lacks crystallizable fragment (Fc) binding activity, was found to be safe and efficacious with prolonged allograft survival (MST = 103 days) and no evidence of thromboembolism in NHPs [124] and is currently under clinical trial (NCT03605927). Here, CD40LG is linked to Thromboembolism.